Type 2 Diabetes Mellitus research hub
31 indexed studies · 24 currently recruiting
- recruitingPHASE3
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
This study looks at new ways to treat type 2 diabetes by testing two medicines, Elecoglipron and Dapagliflozin, both on their own and together. Researchers want to see how well they work and if they are safe for adults with type 2 diabetes.
United States · Argentina · Brazil - recruitingPHASE3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
This study looks at a new medicine called enicepatide for people who are overweight or have obesity and also have type 2 diabetes. We want to see if it helps with weight loss and if it's safe to use.
United States · Argentina · Australia - recruitingPHASE3
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
This study is testing a new medicine, Elecoglipron, for adults with type 2 diabetes and kidney problems. It compares Elecoglipron to a dummy pill (placebo) to see if it's safe and effective when taken with other usual diabetes medicines, including dapagliflozin.
United States · Bulgaria · China - recruitingPHASE3
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
This study compares a new medicine, Elecoglipron, to an existing one, Semaglutide, for adults with Type 2 Diabetes. It aims to see if the new drug is safe and effective for people whose diabetes isn't well-controlled and who have a higher risk of heart problems.
United States · Argentina · Australia - recruitingTherapeutic use (Phase IV)
Open-label, double-arm, controlled, randomized, multicentre clinical trial to evaluate the impact of pharmacogenetic-guided treatment in patients with insufficiently controlled type 2 diabetes
This study looks at whether a simple genetic test can help doctors choose the best medication for people with type 2 diabetes. By matching medicines to a person's DNA, researchers hope to help people lower their blood sugar safely and effectively over 24 weeks.
Spain - recruitingHuman Pharmacology (Phase I)- Other
A Trial to Evaluate Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Insulin GZR4 Compared with Insulin Degludec and Insulin Icodec in Participants with Type 2 Diabetes
This study looks at a new insulin called GZR4 for adults with type 2 diabetes. Researchers want to see how the body absorbs it, how it lowers blood sugar, and how safe it is compared with two existing, approved long-acting insulins, insulin degludec and insulin icodec.
Germany - authorisedTherapeutic confirmatory (Phase III)
A phase III, randomized, prospective, double-blind, parallel design, multi-arm, multicenter study to compare the efficacy and safety of alogliptin and empagliflozin combination therapy versus alogliptin alone and empagliflozin alone in metformin-treated participants with type 2 diabetes mellitus and insufficient glycemic control despite diet and exercise (ODISSEIA 2026).
This study looks at adults with type 2 diabetes who take metformin but still have high blood sugar. Researchers want to see if taking two diabetes medicines together (alogliptin and empagliflozin) lowers blood sugar levels better and more safely than taking either medicine on its own.
Poland · Germany · Portugal - recruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once Weekly s.c. Administered GL0034 in Adults with Type 2 Diabetes Mellitus Inadequately controlled on Metformin Or Diet and Exercise
This study is testing a new weekly medicine, GL0034, for adults with type 2 diabetes whose blood sugar isn't well controlled by metformin or healthy living. We want to see how well it works, if it's safe, and particularly how it affects tummy issues.
Germany - recruitingHuman Pharmacology (Phase I)- Other
A research study comparing different ways of increasing the dose of NNC0519-0130 in participants with overweight or obesity
This study is looking for volunteers to test a new way of giving a medicine called NNC0519-0130. It's for people who are overweight or have obesity and Type 2 diabetes. The aim is to find the best and safest dose.
Austria - recruitingTherapeutic exploratory (Phase II)
A Phase Ilb, Randomized, Double-blind, Placebo controlled and Open-label Active Comparator Study to Evaluate the Efficacy, Safety, and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus
This study is looking at a new medicine called AZD5004 for adults with Type 2 Diabetes. Researchers want to see how well it lowers blood sugar (HbA1c) and if it's safe, compared to a widely used medicine (Rybelsus) or a dummy pill.
Hungary · Germany · Poland - recruitingTherapeutic use (Phase IV)
Intraclass safety and efficacy comparison among SGLT-2 inhibitors in elderly patients with type 2 diabetes. A pragmatic, phase IV, multicenter, open-label, randomised controlled trial.
This study is looking at how well different diabetes medicines, like Invokana and Forxiga, work and how safe they are for older people with type 2 diabetes. The main goal is to see if these medicines help control blood sugar without causing dangerously low levels.
Italy - recruitingHuman Pharmacology (Phase I)- Other
A Phase I Randomized, Single-center, Double-blind, Two-period Crossover Trial to Evaluate Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Insulin GZR4 Compared with Insulin Icodec in Participants with Type 2 Diabetes.
This study is testing a new type of insulin, called Insulin GZR4, against another insulin, Insulin Icodec, for people with type 2 diabetes. We want to see how they work in the body, if they are safe, and if people can tolerate them well. It's an early-stage study.
Germany - recruitingPhase I and Phase II (Integrated)- Other
A single-center pilot study to establish a novel hypoglycemic clamp procedure to assess the time to spontaneous recovery from hypoglycemia in people with and without diabetes
This study looks at how people with and without type 2 diabetes recover from low blood sugar. Researchers use a special method to see how much insulin is needed to lower blood sugar and how long it takes for it to naturally return to normal after becoming very low.
Austria - recruitingHuman Pharmacology (Phase I)- Other
A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia
This study is looking at how a new weekly medicine called Retatrutide affects people with type 2 diabetes, specifically how their bodies handle low blood sugar levels. It's an early-stage study to understand how this medicine works in people.
Austria - completed
The influence of whey protein on free-living glycaemic control in type 2 diabetes
Researchers in Newcastle are testing whether drinking a small whey protein shot before meals helps adults with type 2 diabetes manage blood sugar at home. Participants drink small protein beverages before breakfast, lunch, and dinner, wear a blood sugar monitor, and attend hospital test days to see how their bodies respond.
United Kingdom · England - recruitingPhase IV
Initiation and management of DExcom continuous glucose monitoring in primary care in people living with type 2 diabetes on insulin
This study looks at how a glucose monitoring system (Dexcom ONE+) works in UK GP practices for people with type 2 diabetes on insulin. It aims to see if it helps manage blood sugar and fits into routine care.
United Kingdom · England · Ireland - recruitingHuman Pharmacology (Phase I)- Other
A study to assess the pharmacokinetics, and glucodynamics of LY3209590 in participants with type 2 diabetes
This study is looking at a new medicine, LY3209590, for people with type 2 diabetes. Researchers want to understand how it works in the body and how it affects blood sugar levels. It's an early-stage study to gather important information about this potential new treatment.
Germany - completedNot Applicable
Looking at the effect of the smart multiple daily injections (MDI) system (inPen™) in type 2 diabetes
This study looks at a new smart insulin pen system called InPen™ for people with Type 2 diabetes. It aims to see if this smart pen, which links to a sensor and app, works better than standard pens to manage blood sugar. Up to 78 UK adults will take part.
United Kingdom · England - recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Study to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729) in Pediatric Participants (ages 10 to 17 years, inclusive) with Type 2 Diabetes Mellitus (MK-8835-059/B1521066)
This study is looking at a new medicine called ertugliflozin for young people aged 10 to 17 with type 2 diabetes. We want to see if it helps control blood sugar and if it's safe compared to a dummy pill.
Poland · Italy · Hungary - completed
Smart technology for diabetic foot monitoring
This study looks at smart socks to help people with Type 2 diabetes. It aims to measure pressure on the feet during walking to prevent serious foot problems like ulcers. Researchers want to see if these socks can spot early signs of nerve damage in the feet. Join if you have Type 2 diabetes and can walk.
United Kingdom · England - recruitingTherapeutic confirmatory (Phase III)
Effects of Finerenone on Renal Hemodynamics and Oxidative Stress
This study is looking at how a medicine called Kerendia (finerenone) affects the kidneys in people with type 2 diabetes. It aims to see if Kerendia can help improve kidney function by reducing stress on kidney blood vessels, compared to a dummy pill.
Germany - recruitingHuman Pharmacology (Phase I)- First administration to humans
A research study Looking into blood levels of the medicine NNC0519-0130 in the body of participants with normal or reduced kidney function
This study is looking at a new medicine, NNC0519-0130, for people with Type 2 Diabetes. Researchers want to see how much of the medicine stays in the blood and for how long, especially in people with normal or reduced kidney function. It's an early-stage study to understand the medicine better.
Germany - recruitingTherapeutic confirmatory (Phase III)
I8F-MC-GPGN: The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes (SURPASS-CVOT)
This study compares two medicines, tirzepatide and dulaglutide, for people with type 2 diabetes. It looks at how well they protect against serious heart problems like heart attacks and strokes. It's a big, important study to confirm which medicine is better for your heart.
Slovakia · France · Hungary - recruitingHuman Pharmacology (Phase I)- Other
Exploratory Bioavailability of Two Formulations of Gliclazide MR Tablets 120 mg (I.R.I.S.) in Healthy Volunteers Under Fed and Fasting Conditions.
This study is looking at how two different versions of a diabetes medicine called gliclazide MR 120 mg are absorbed by the body. We want to see if food affects how well they work in healthy adults.
Portugal - active not recruitingPHASE1
A Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants With Type 2 Diabetes Mellitus (T2DM) and Overweight or Obesity
This study looks at a new drug, RO7204239, for people with type 2 diabetes who are overweight or have obesity. It aims to see if the drug can improve how the body uses insulin and affects muscle health. This is an early stage study.
Germany - recruitingPHASE3
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
This study is looking at a new tablet, ASC30, for adults who have obesity or are overweight and also have type 2 diabetes. It's a large study that compares the new tablet to a dummy pill (placebo) to see how well it works for managing weight and its safety over time.
United States · Czechia · Germany - recruitingPHASE3
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
This study, called Proact, is investigating a new treatment called REACT (also known as rilparencel) for people with type 2 diabetes and chronic kidney disease. Researchers want to see if this treatment can help kidney function and if it is safe.
United States · Australia · Canada - recruiting
An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions
This study looks at how a new medicine, finerenone, is used by people in everyday life. It's for people with long-term kidney problems and type 2 diabetes. Researchers will check if it's safe and how well it works using existing health records, not new tests.
United States · Germany · Japan - authorisedTherapeutic use (Phase IV)
Impact of GLP1-RAs on inflammation and endothelial biomarkerS in Type 2 diABetes meLlitus patiEnts: STABLE-GLP1 trial.
This study looks at how a diabetes medicine, semaglutide, affects inflammation and blood vessel health in people with Type 2 diabetes. We want to see if adding semaglutide to regular treatment helps reduce harmful effects in the body compared to standard treatment alone.
Italy - not yet recruitingNA
Effect of Beetroot Juice on Cardiovascular and Autonomic Responses to Exercise in Adults With Type 2 Diabetes
This study looks at whether beetroot juice can help adults with Type 2 Diabetes recover better after exercise. It checks how exercise affects blood pressure and heart rate, as well as how helpful beetroot juice might be with these effects.
United Kingdom - active not recruitingPHASE2
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin
This study is testing two natural substances, Apelin and Relaxin, to see how they affect blood flow and body processes in people with heart conditions or type 2 diabetes. We want to find new ways to improve health for these conditions.
United Kingdom